Interstitial pneumonia disease induced by osimertinib combined with savolitinib targeted therapy in a lung cancer patient: A case report

Yikuan Shen,Songgao Lou,Jiansong Zhang

DOI: https://doi.org/10.1097/md.0000000000036208

IF: 1.6

2024-01-11

Medicine

Abstract:Lung cancer is a common disease with increasing morbidity and mortality worldwide. [ 1 ] According to China national statistics, there are about 631,000 lung cancer deaths every year, and Chinese lung cancer patients have the characteristics of high epidermal growth factor receptor (EGFR) mutations. [ 2 ] In patients with advanced NSCLC with EGFR-sensitive mutations, EGFR-TKIs significantly improved objective response rate and progression-free survival compared with conventional chemotherapy. [ 3 ] METex14 skipping mutations occur in approximately 3–4% of lung adenocarcinoma patients, [ 4 ] and 5%-20% in EGFR-TKIs-resistant patients. [ 5 ] Savolitinib, was conditionally approved in China for advanced NSCLC with METex14 jumping mutations, [ 6 ] and savolitinib as a late-line treatment for patients with MET14 exon-skipping mutation NSCLC had an objective response rate of 49.2% and progression-free survival of 6 months. [ 7 ] Common adverse reactions of MET-TKI are peripheral edema, nausea, elevated alanine transaminase, elevated aspartate transaminase, vomiting, hypoalbuminemia, and decreased appetite; interstitial lung disease is a rare adverse reaction. [ 8 ]

medicine, general & internal